Pressure BioSciences (PBIO)
(Delayed Data from OTC)
$0.22 USD
-0.01 (-4.35%)
Updated Apr 25, 2024 01:32 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Pressure BioSciences Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | NA | 2 | 2 | 1 | 2 |
Cost Of Goods | NA | 2 | 1 | 1 | 1 |
Gross Profit | NA | 0 | 1 | 1 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 5 | 5 | 5 | 6 |
Income After Depreciation & Amortization | 0 | -5 | -4 | -5 | -6 |
Non-Operating Income | NA | -1 | -2 | -3 | -1 |
Interest Expense | NA | 10 | 14 | 8 | 5 |
Pretax Income | NA | -16 | -20 | -16 | -12 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -16 | -20 | -16 | -12 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -16 | -20 | -16 | -12 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -3 | 3 | 1 | -4 |
Depreciation & Amortization (Cash Flow) | NA | 2 | 7 | 6 | 1 |
Income After Depreciation & Amortization | 0 | -5 | -4 | -5 | -6 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 11.06 | 6.64 | 3.30 | 1.99 |
Diluted EPS Before Non-Recurring Items | NA | -1.61 | -3.42 | -5.32 | -7.98 |
Diluted Net EPS (GAAP) | NA | -1.61 | -3.42 | -5.32 | -7.98 |
Fiscal Year end for Pressure BioSciences Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | NA | 0.41 | 0.51 | 0.74 |
Cost Of Goods | NA | NA | 0.23 | 0.26 | 0.36 |
Gross Profit | NA | NA | 0.18 | 0.26 | 0.38 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 1.48 | 1.34 | 4.02 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | -1.30 | -1.08 | -3.64 |
Non-Operating Income | NA | NA | 0.00 | 0.04 | 0.67 |
Interest Expense | NA | NA | 4.34 | 5.88 | 3.89 |
Pretax Income | NA | NA | -5.63 | -6.92 | -6.86 |
Income Taxes | NA | NA | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | NA | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | NA | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | NA | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | NA | -5.63 | -6.92 | -6.86 |
Extras & Discontinued Operations | NA | NA | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | NA | -5.63 | -6.92 | -6.86 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 21.72 | 19.47 | 15.84 |
Diluted EPS Before Non-Recurring Items | NA | NA | -0.29 | -0.57 | -0.46 |
Diluted Net EPS (GAAP) | NA | NA | -0.29 | -0.57 | -0.46 |